TCM treatment strategy of peritoneal injury induced by microinflammatory status in peritoneal dialysis

doi:10.3877/cma.j.issn.2095-3216.2019.05.008

Abstract

Abstract:

Peritoneal dialysis (PD) patients generally have microinflammation of different degrees. The microinflammation in PD patients participates in and mediates peritoneal injury, promotes the development of peritoneal fibrosis, and seriously affects the quality of life and survival rate of PD patients. Currently, there is a lack of specific clinical drugs for prevention and treatment of microinflammation in PD patients. Traditional Chinese medicine (TCM) believes that spleen deficiency, qi weakness, and toxic damage to the abdominal collaterals are the main pathogenesis for PD microinflammation to induce peritoneal injury. The method of strengthening spleen and replenishing qi can prevent and treat the peritoneal injury induced by PD microinflammation so as to protect the peritoneal function. Under the guidance of TCM theory, it will provide new methods for prevention and treatment of the PD microinflammation with TCM, to combine the understanding of the mechanism of peritoneal injury induced by PD microinflammation with the modern medicine, in order to form a TCM system for preventing and treating the PD microinflammation-related peritoneal injury.

Key words: Peritoneal dialysis, Microinflammatory status, Prevention and treatment with traditional Chinese medicine, Strengthening spleen and replenishing qi

Duanyun Yang, Yujuan Wu, Wei Shi, Junming Fan, Lifeng Meng. TCM treatment strategy of peritoneal injury induced by microinflammatory status in peritoneal dialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(05): 230-233.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2019.05.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2019/V08/I05/230

References 35

[1]	Yao Q, Duddington M. Peritoneal dialysis in China [J]. Perit Dial Int, 2014, 34(1): S29-S30.
[2]	范汝燕，翁宁，徐佳美．持续性非卧床腹膜透析患者退出原因分析[J]．中国中西医结合肾病杂志，2008，9(8)：708-709.
[3]	Sehomig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia [J]. Blood Purlf, 2000, 18(2): 327-332.
[4]	董捷，王海燕．腹膜透析患者慢性炎症状态与营养不良及心血管病的关系[J]．中华肾脏病杂志，2002，18(5)：317-321.
[5]	Wang AY. Consequences of chronic inflammation in peritoneal dialysis [J]. Semin Nephrol, 2011, 31(2): 159-171.
[6]	吴晶晶，袁杨刚，黄抱娣，等．腹膜透析患者第一年死亡的危险因素分析[J]．肾脏病与透析肾移植杂志，2014，23(6)：528-531.
[7]	秦超师，李晓艳，蒋学俊，等．微炎症反应状态与钙化[J]．中国组织工程研究，2015，19(29)：4721-4725.
[8]	Wang AY, Lam CW, Chan IH, et al. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers [J]. Nephrol Dial Transplant, 2009, 24(12): 3826-3833.
[9]	Peeoits-Filho R, Stenvinkel P, Wang AY, et al. Chronic inflammation in peritoneal dialysis: the search for the holy grail? [J]. Perit Dial Int, 2004, 24(4): 327-339.
[10]	Lai KN, Leung JC. Inflammation in peritoneal dialysis [J]. Nephron Clin Pract, 2010, 116(1): c11-c18.
[11]	Diaz-Buxo JA, Himmele R. Strategies to universally improve peritonitis rates, including use of dialysis solutions with low glucose degradation products [J]. Adv Perit Dial, 2010, 26(4): 37-40.
[12]	陈坤，张琳．腹膜透析患者微炎症状态及中医药干预的研究进展[J]．云南中医药杂志，2019，40(1): 76-78.
[13]	Munguía-Miranda C, Ventura-García Mde J, Ávila-Díaz M, et al. Factors related to residual renal function loss in patients in peritoneal dialysis [J]. Rev Med Inst Mex Seguro Soc, 2015, 53(5): 578-583.
[14]	Zhou L, Wen F, Chen G, et al. Cytokine profiles in peritoneal dialysis effluent predicts the peritoneal solute transport rate in continuous ambulatory peritoneal dialysis patients [J]. Int J Clin Exp Med, 2015, 8(11): 20424-20433.
[15]	王涵，俞雨生．微炎症状态与腹膜透析[J]．肾脏病与透析肾移植杂志，2012，21(2): 183-189.
[16]	黄成文，郑庆发，石咏军，等．持续性非卧床腹膜透析患者微炎症状态影响因素分析及利尿剂对其微炎症状态的影响[J]．广东医学，2014，35(2): 226-228.
[17]	EllionIm DA. Nutritional considerations for the dialytic patient [J]. Vet Clin North Am Small Pract, 2011, 41(1): 239-250.
[18]	王红，吴歌，赵占正，等．腹膜透析患者脂质代谢紊乱与微炎症状态的关系[J]．郑州大学学报(医学版)，2012，47(4): 547-550.
[19]	Fliser D, Buchholz K, Haller H, et al. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation [J]. Circulation, 2004, 110(9): 1103-1107.
[20]	刘金凤，韩洪波，王芹，等．大黄联合辛伐他汀对腹膜透析患者微炎症状态的影响[J]．哈尔滨医科大学学报，2013，47(5): 446-448.
[21]	段明亮，张琳琪．小柴胡汤合五苓散对维持性腹膜透析患者残余肾功能的保护及对腹膜纤维化、微炎症状态的影响．[J]．中国实验方剂学杂志，2018，24(24): 1-6.
[22]	李真，盛梅笑．微炎症在腹膜透析中的作用及研究进展[J]．河南中医，2015，35(3): 656-658.
[23]	孙响波，王霞，于妮娜．苏叶地黄汤对慢性肾功能衰竭患者"微炎症状态"的影响[J]．河南中医，2016, 36(3)：545-546.
[24]	孟立锋，谢桂权．谢桂权从浊毒论治慢性肾衰竭经验[J]．中华中医药杂志，2016，17(4): 1301-1303.
[25]	谢永祥，龙春莉，陶志虎，等．益肾补脾法对慢性肾脏病3期患者微炎症、氧化应激及营养状态的影响[J]．中国中西医结合肾病杂志，2016, 17(1)：54-56.
[26]	孟立锋，史伟．从痰瘀互结论腹膜纤维化的病因病机[J]．新中医，2012，44(8)：200-201.
[27]	盛梅笑，许陵冬，江燕，等．腹膜透析患者中医证型研究及其影响因素的临床观察[J]．中国中国中西医结合肾病杂志，2014，15(1)：30-33.
[28]	吴一帆，刘旭生，黄春林，等.156例维持性腹膜透析患者中医证型分析[J]．中国中西医结合杂志，2010，30(2)：146-149.
[29]	孟立锋，谢永祥，陶志虎，等．健脾化痰祛瘀方防治腹透患者腹膜纤维化60例临床研究[J]．中医临床研究，2015，7(30)：70-73.
[30]	冼启经．健脾益气法干预维持性腹膜透析相关营养不良的临床观察[J]．云南中医中药杂志，2013，34(9)：29-30.
[31]	张晓春，张惠霞，王力宁，等．健脾益气合剂改善抗生素脱污染小鼠肠道菌群失调及细菌移位的实验研究[J]．中医儿科杂志，2012，32(6): 7-10.
[32]	孟立锋，史伟，王夏青，等．中医药防治腹膜透析相关性腹膜纤维化研究进展[J/CD]．中华肾病研究电子杂志，2018，7(3): 131-134
[33]	Chen Y, Gui D, Chen J, et al. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats [J]. Cell Physiol Biochem, 2014, 33(6): 1975-1987.
[34]	孟立锋，杨端云，史伟，等．健脾益气方改善腹膜透析大鼠微炎症状态诱导腹膜损伤的作用及机制研究[J]．辽宁中医杂志，2019，49(5): 1066-1070.
[35]	孟立锋，李吉武，蓝芳．从"风性开泄"理论探讨风药治疗肾性蛋白尿的机制[J]．中医药通报，2013，12(3)：34-35.

Please choose a citation manager

Content to export